62-0566-42

antibody from Invitrogen Antibodies

Targeting: NCAM1 CD56, NCAM

Provider product page for 62-0566-42

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [5]
Comments [0]
Validations
Flow cytometry [2]
Other assay [5]

Submit

Product number: 62-0566-42 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD56 (NCAM) Monoclonal Antibody (TULY56), Super Bright™ 436, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: This TULY56 monoclonal antibody reacts with human CD56, also known as Neural Cell Adhesion Molecule (NCAM). CD56 is a highly glycosylated transmembrane molecule expressed by neurons and plays a role in the homotypic adhesion of neural cells. In the hematopoietic system, CD56 is expressed on NK cells and a subset of T cells referred to as NKT cells. Staining with TULY56 does not block binding of CMSSB, suggesting that the two antibodies recognize different epitopes. Additionally, TULY56 performs better after fixation and permeabilization than CMSSB. The TULY56 monoclonal antibody crossreacts with Rhesus macaque. Applications Reported: This TULY56 antibody has been reported for use in flow cytometric analysis. Applications Tested: This TULY56 antibody has been pre-diluted and tested by flow cytometric analysis of normal human peripheral blood cells. This may be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm. We recommend using a 450/50 bandpass filter, or equivalent. Please make sure that your instrument is capable of detecting this fluorochrome. When using two or more Super Bright dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer for more information. Excitation: 405 nm; Emission: 436 nm; Laser: Violet Laser Super Bright Polymer Dyes are sold under license from Becton, Dickinson and Company.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: TULY56
Vial size: 100 Tests
Concentration: 5 µL/Test
Storage: 4° C, store in dark, DO NOT FREEZE!

NCAM1 protein structure - 62-0566-42 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Characterization of Myogenic Progenitors Derived from iPSCs via VP64 dCas9 VP64 -Mediated Activation of Endogenous PAX7 or Exogenous PAX7 cDNA Expression (A) Relative amounts of total PAX7 mRNA was determined by qRT-PCR using primers complementary to sequences present in the gene body. (B) Endogenous PAX7 mRNA was detected using primers complementary to sequences in the 3' UTR of either isoform PAX7-A or PAX7-B . (C) The mRNA expression levels of myogenic markers MYF5 , MYOD , and MYOG during the expansion phase. (D) Immunofluorescence staining of early and mature myogenic markers MYF5, MYOD, and MYOG, and myosin heavy chain (MHC). (E) Representative FACS analysis of CD29 and CD56 surface marker expression during the expansion phase. (F) Mean fluorescence intensity (MFI) of CD56 staining intensity across treatments. All p values were determined by one-way ANOVA followed by Tukey's post hoc test (mean +- SEM, n = 3 independent replicates).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Immune profiling in DENV-treated whole blood cells 24 h postincubation. Following DENV (MOI = 1) coculture in 100 mu l of WB ex vivo for 24 h, (a) representative flow cytometric analysis and gating of various cells obtained from five cases, performed by staining for specific cell surface markers (CD4, CD8, CD11c, CD14, CD16, CD19, CD25, CD56, CD62L, and HLA-DR), in the DENV-infected and mock groups showed (b) the changes in the expression of specific immune cell populations as noted. (c) The results are shown as a percentage of the mean +- SD obtained from five cases. * p < 0.05, ** p < 0.01, and *** p < 0.001, compared to the mock group. R: region; WBC: white blood cell; bri: bright.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 CD56 enhanced anti-apoptosis capability of CAR-T cells. a Left panel, the representative flow plots of apoptotic cell proportion in Her2-CAR-T, PTL-Her2-CAR-T, and CD56-Her2-CAR-T cells after culture for 6 days with cytokine deprivation. Right panel, the percentage of Annexin V - and PI - cells gated as in left panel. b Left panel, the representative flow plots of apoptotic cell proportion induced by TNF-alpha and FasL (10 ng ml -1 ) in various CAR-T cells. Right panel, the percentage of Annexin V - and PI - cells gated as in the left panel. ** P < 0.01, **** P < 0.0001 (two-tailed Student's t -test). All presented data summarizes mean +- SEM. Data shown are representative data from three independent experiments. The source data underlying a , b are provided as a Source Data file

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Transcriptional signature of functionally mature NK cells. a Representative genes associated with functionally mature NK cells were grouped in four different categories and plotted via violin plots of the BM sample. The y -axis represents log-normalized expression value. b The expression of ANXA1 , ANXA2 , and ANXA6 in each cluster of the blood sample was shown as violin plots. The y -axis represents log-normalized expression value. c The intracellular protein level of Annexin A1 in different NK cell subsets from blood at steady state was assessed by flow cytometry. The representative histogram was shown on the left. FMO stands for fluorescence minus one. The mean fluorescence intensity (MFI) of Annexin A1 in each NK subsets was normalized to CD56 bright NK subset and shown on the right. n = 5 from three independent experiments. Error bars were shown as standard deviation. One-way ANOVA was used for the statistical analysis. * P < 0.05; ** p < 0.01; *** p < 0.001. d Isolated NK cells from blood were stimulated with medium, IL-12, and IL-18 (10/10 ng/mL), or PMA and ionomycin (50/500 ng/mL) for 6 h. The protein level of Annexin A1 was assessed following stimulation. The MFI of Annexin A1 in each condition was normalized to the medium-only NK cells. n = 5 from three independent experiments. Error bars were shown as standard deviation. One-way ANOVA was used for the statistical analysis. * P < 0.05; ** p < 0.01; *** p < 0.001. e Isolated NK cells from blood were stimulate

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 CG-745 increases helper T cells, cytotoxic T cells and natural killer T cells, and decreases Treg: (A) hPBMCs were incubated with CG (CG-745) for 36 hours and a subset of hPBMCs was analyzed using the antibodies indicated in the text; (B) hPBMCs were co-cultured with Huh7, Hep3B, HepG2 or PLC/PRF/5 cells for 36 hours with or without CG, and a subset of hPBMCs was analyzed by Attune Nxt (Invitrogen, USA).